Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
List view / Grid view
National Institute for Health and Care Excellence (NICE)
The next Chief Executive of the National Institute for Health Research’s Clinical Research Network has been announced as Dr William van’t Hoff.
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
The European Commission has given its approval to Keytruda to treat head and neck squamous cell carcinoma as a monotherapy or in combination with a chemotherapy.
Lanadelumab, a preventive treatment for hereditary angioedema, has been recommended as a cost-effective use of NHS resources.
The voretigene neparvovec gene therapy treatment has been highlighted in draft guidance by NICE for availability on the NHS.
NICE and GW Pharma will work together to address the issues highlighted in its evaluation of cannabidiol for treating two types of epilepsy.
The NICE and NHS have announced their draft recommendations for the prescribed use of cannabis-based treatments.
Lokelma, a treatment for hyperkalaemia in adults, has received a positive Final Appraisal Document from NICE after successful trials.
NICE has issued a recommendation for risankizumab to treat patients with severe plaque psoriasis.
The NHS is set to launch a new payment method for antibiotic development to incentivise pharmaceutical companies.
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.
NICE in the UK and its counterpart - the Canadian Agency for Drugs and Technology in Health have collaborated to offer parallel scientific advice...